{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Participants in a study or treatment group who are still alive for a certain period of time after they were diagnosed with or started treatment for a disease","groups":[{"description":"Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles","id":"OG000","title":"Treatment (Pembrolizumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Time of start of treatment to death from any cause up to 2 years and 6 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Participants"}